U.S. Markets close in 4 hrs 50 mins

Clovis Oncology, Inc. (CLVS)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
70.99-0.21 (-0.29%)
As of 11:10AM EDT. Market open.
People also watch
Full screen
Previous Close71.20
Bid70.58 x 100
Ask70.65 x 100
Day's Range70.47 - 71.90
52 Week Range16.61 - 99.45
Avg. Volume1,936,701
Market Cap3.47B
PE Ratio (TTM)-8.74
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com4 days ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com4 days ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • Market Realist4 days ago

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts ...